Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discussion of Research Priorities for Gait Disorders in Parkinson's Disease.
Bohnen NI, Costa RM, Dauer WT, Factor SA, Giladi N, Hallett M, Lewis SJG, Nieuwboer A, Nutt JG, Takakusaki K, Kang UJ, Przedborski S, Papa SM; MDS-Scientific Issues Committee. Bohnen NI, et al. Among authors: factor sa. Mov Disord. 2022 Feb;37(2):253-263. doi: 10.1002/mds.28883. Epub 2021 Dec 22. Mov Disord. 2022. PMID: 34939221 Free PMC article. Review.
Physiology of freezing of gait.
Snijders AH, Takakusaki K, Debu B, Lozano AM, Krishna V, Fasano A, Aziz TZ, Papa SM, Factor SA, Hallett M. Snijders AH, et al. Among authors: factor sa. Ann Neurol. 2016 Nov;80(5):644-659. doi: 10.1002/ana.24778. Epub 2016 Oct 7. Ann Neurol. 2016. PMID: 27649270 Review.
Reply to: "Letter on Discussion of Gait Research".
Bohnen NI, Costa RM, Dauer WT, Factor SA, Giladi N, Hallett M, Lewis SJG, Nieuwboer A, Nutt JG, Takakusaki K, Kang UJ, Przedborski S, Papa SM. Bohnen NI, et al. Among authors: factor sa. Mov Disord. 2022 Jun;37(6):1328. doi: 10.1002/mds.29049. Mov Disord. 2022. PMID: 35707827 No abstract available.
Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications.
Espay AJ, Guskey MT, Norton JC, Coate B, Vizcarra JA, Ballard C, Factor SA, Friedman JH, Lang AE, Larsen NJ, Andersson C, Fredericks D, Weintraub D. Espay AJ, et al. Among authors: factor sa. Mov Disord. 2018 Nov;33(11):1769-1776. doi: 10.1002/mds.27488. Epub 2018 Nov 2. Mov Disord. 2018. PMID: 30387904 Free PMC article. Clinical Trial.
Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial.
Patterson CG, Joslin E, Gil AB, Spigle W, Nemet T, Chahine L, Christiansen CL, Melanson E, Kohrt WM, Mancini M, Josbeno D, Balfany K, Griffith G, Dunlap MK, Lamotte G, Suttman E, Larson D, Branson C, McKee KE, Goelz L, Poon C, Tilley B, Kang UJ, Tansey MG, Luthra N, Tanner CM, Haus JM, Fantuzzi G, McFarland NR, Gonzalez-Latapi P, Foroud T, Motl R, Schwarzschild MA, Simuni T, Marek K, Naito A, Lungu C, Corcos DM; SPARX3-PSG Investigators. Patterson CG, et al. Trials. 2022 Oct 6;23(1):855. doi: 10.1186/s13063-022-06703-0. Trials. 2022. PMID: 36203214 Free PMC article.
287 results